| C46 | WeChat reminders to improve the willingness to undergo voluntary medical male circumcision for HIV prevention among men who have sex with men: a randomized controlled trial | E-poster | Use of the Internet, social media, mobile phones and other e-devices for prevention |
| B39 | Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) | On-demand oral abstract session | Long-acting agents and other drug delivery systems |
| B35 | Week 72 outcomes and COVID-19 impact from The BRAAVE 2020 study: a randomized switch to B/F/TAF in African American adults living with HIV | E-poster | Regimen simplification and switch studies |
| B32 | Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirine | E-poster | ART in first- and second-line therapies |
| B33 | Weight changes in HIV+ individuals receiving ibalizumab over 96 weeks | E-poster | ART in highly treatment-experienced people |
| B24 | Weight changes, metabolic syndrome and all-cause mortality in persons living with HIV | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight gain following the single substitution of TDF by TAF in people living with HIV (PLWH) in the French Dat'AIDS cohort | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B61 | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B24 | Weight gain or 'return to health'? Changes in body weight in aging people living with HIV compared with the general population from the German Ruhr-area over 5 years | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B62 | What are the drivers of improved viral suppression among HIV infected children (0-14 years)? Results from the national data warehouse in Kenya 2020 | E-poster | ARV management strategies in paediatric and adolescent populations |